Aducanumab for Alzheimer's disease?

BMJ. 2021 Jul 5:374:n1682. doi: 10.1136/bmj.n1682.

Authors

Sebastian Walsh¹, Richard Merrick², Richard Milne³, Carol Brayne²

Affiliations

¹ Cambridge Public Health, University of Cambridge, Cambridge, UK sjw261@medschl.cam.ac.uk.
² Cambridge Public Health, University of Cambridge, Cambridge, UK.
³ Society and Ethics Research Group at Wellcome Connecting Science, Cambridge, UK.

Abstract

Patients and families need hope, not false hope

Publication types

Editorial

MeSH terms

Alzheimer Disease / drug therapy*
Antibodies, Monoclonal, Humanized / therapeutic use*
Drug Approval
Humans
United States

Substances

Antibodies, Monoclonal, Humanized
aducanumab

Grants and funding